Treatment with subeffective doses of γ-tocotrienol (2 μM), the PPARγ antagonist, GW9662 (3.2 μM), alone had no significant effect on COX-2 and PGDS levels in vehicle-treated and scrambled RNA transfected MCF-7 (Figure 9(c)) and MDA-MB-231 (Figure 9(d)) breast cancer cells. Here, PPARG is linked to breast carcinoma.